Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the response rate and response duration with the
combination of low-dose rituximab and high-dose dexamethasone in the treatment of adult
immune thrombocytopenic purpura.